Use access key #2 to skip to page content.
$10.58 -0.13 (-1.21%)
7/3/2008 1:04 PM

King Pharmaceuticals, Inc. (KG)

CAPS Rating:
****

The Company is a vertically integrated pharmaceutical company that develops, manufactures, markets and sells branded prescription pharmaceutical products.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating KG

Add Stock to Watchlist

What the Community Thinks Add a widget featuring this stock to your blog!

Total Players

326 Outperforms
26 Underperforms
 

All-Stars

65 Outperforms
7 Underperforms
 

Wall Street

2 Outperforms
1 Underperforms
 

Players bullish on KG are also bullish on:

Players bearish on KG are also bearish on:

Ticker Tags

Drug Manufacturers - Other (105), Small Cap (1922), S&P 500 (482)
Suggest a tag

King Pharmaceuticals, Inc. At A Glance

Current Price: $10.58
Last Trade Time: 7/3/2008 1:04 PM
Open: $0.00
Previous Close: $10.71
Daily Range: $10.40 - $10.89
52-Week Range: $8.26 - $21.10
Volume: 1,678,542
Market Cap: $2.64B
P/E Ratio: 17.00
Compare Our Special Broker Offers!

Stock Trends

KG VS S&P 500 (SPY)

KG 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for KG

More Headlines...

Top Bull Pitch

Recs

5

King Pharmaceuticals, Inc. (KG)

Avatar xthecritic (88.20) Submitted: 2/07/08 12:42 PM

Anybody like cash flow? King pumped out a billion dollar of cash flow in the last 12 months and is valued at $2.5 bil. With another $400mm of debt that makes them a $3 bil company trading at 3x trailing cash flow. Wow. That is cheap. The earnings took a beating and the forward outlook is for lo...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

2

King Pharmaceuticals, Inc. (KG)

Avatar TrackZacks (90.39) Submitted: 6/21/07 5:56 PM

Sell King Pharmaceuticals

Posted Thu Jun 21, 09:14 am ET
by Zacks Equity Research

Though in recent weeks shares of King Pharmaceuticals (KG) have appreciated in price, Zacks senior pharmaceuticals analyst Jason Napodano, CFA is keeping his Sell rating on KG at this time. To find out why, we loo...More

Replies: 0 | Reply | Permalink

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 48 :   1 2 3 4 5 Next » Jump to page:

Recs

0

 (KG)

Avatar Dragontoad2 (58.20) Submitted: 7/02/08 9:14 AM : Outperform Start Price: $10.50 KG Score: 2.80

price/book =1.. solid numbers

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (KG)

Avatar NASAGeek (< 20) Submitted: 6/26/08 9:21 PM : Outperform Start Price: $9.91 KG Score: 8.40

magicformulainvesting.com screen at $153M market cap, top 25 companies on June 26, 2008

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (KG)

Avatar twistright (42.83) Submitted: 6/11/08 7:38 PM : Outperform Start Price: $9.40 KG Score: 18.85

increase in businesses offering fixed price prescriptions will boost near term demand for generics.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (KG)

Avatar ResearchLover (86.75) Submitted: 6/04/08 12:43 PM : Outperform Start Price: $10.02 KG Score: 14.49

King pharmaceuticals has some products which generate great cash flow. It was supposed to weather the downturn better than it did. And now its discounted P/E reflects that.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (KG)

Avatar angus118 (30.46) Submitted: 5/22/08 11:48 AM : Outperform Start Price: $9.85 KG Score: 16.81

King Pharmaceuticals KG has been hurt by the loss of a patent dispute last year for the key ingredient in its hypertension drug Altace. The result has been generic competition for the drug much sooner than anticipated and this is having a negative effect on revenues and margins. As a result King has laid off 20% of its work and refocused its efforts on the neuroscience, hospital and acute care markets. The neuroscience division in particular could be very attractive should they receive FDA approval for their abuse resistant pain drug Remoxy. They hope to have the drug to market by 2009 and it is a potential blockbuster. The stock trades just off its 52-week lows and has a bulletproof balance sheet with over 60% of the stock price in cash. The EV/EBITDA ratio is just 1.5 and equally attractive to the asset-loving side of me, it trading at 85% of book value. It is worth a look at these levels. Tim Melvin - thestreet.com

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 48 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 3 of 3  

picks per page. CHANGE Expand All Pitches

Top
Pick
Player NamePlayer RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackJGreenblatt < 20 04/11/08 Outperform 1Y $8.88+19.14%-5.82%+24.96 Toggle the visibility of 60-Second Pitch and replies
TrackSoros < 20 09/30/07 Outperform NS $11.72-9.73%-17.22%+7.49 Toggle the visibility of 60-Second Pitch and replies
TrackZacks 90.39 06/21/07 Underperform 3M $20.51-48.42%-16.89%+31.53 Toggle the visibility of 60-Second Pitch and replies
TrackJimCramer 83.36 06/09/06 Underperform 3W $16.50-35.88%+0.41%+36.29

Results 1 - 3 of 3  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners